-- PDUFA Date Set for February 17, 2022 -- -- PDUFA Date Set for February 17, 2022 --
Follow this link:
Agios Announces FDA Acceptance and Priority Review of New Drug Application for Mitapivat for Treatment of Adults with Pyruvate Kinase Deficiency
COPENHAGEN, Denmark, Aug. 17, 2021 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical company that utilizes its innovative TransCon™ technologies to create product candidates that address unmet medical needs, today announced that the company will hold a conference call and live webcast on Wednesday, August 25, 2021 at 4:30 p.m. Eastern Time (ET) to review its second quarter 2021 financial results and provide a business update.
Go here to see the original:
Ascendis Pharma A/S Announces Second Quarter 2021 Financial Results and Business Update Conference Call on August 25
SAN DIEGO, Aug. 17, 2021 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on emerging immune control mechanisms applicable to inflammation and immuno-oncology indications, today announced that the U.S. Food and Drug Administration (FDA) approved a second indication for GSK’s JEMPERLI (dostarlimab-gxly) for the treatment of adult patients with mismatch repair deficient (dMMR) recurrent or advanced solid tumors, as determined by an FDA-approved test, that have progressed on or following prior treatment and who have no satisfactory alternative treatment options.
See the article here:
FDA Grants Accelerated Approval of JEMPERLI (dostarlimab-gxly) for dMMR Recurrent or Advanced Solid Tumors
NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR DISSEMINATION IN THE UNITED STATES
View post:
ProMIS Neurosciences Inc. Announces US$15 Million Offering of Units
TORONTO, Aug. 17, 2021 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, is pleased to announce that Revive has entered into an exclusive license agreement (the “Agreement”) with Puerto Rico Science Technology and Research Trust (“PRSTRT”), representing Universidad Central del Caribe (“UCC”) and St. Jude Children’s Research Hospital (“St. Jude”), for the intellectual property (International Patent Application No. PCT/US2020/017053/) titled, Biologically Active Ganoderma Lucidum Compounds and Synthesis of Anticancer Derivatives; Ergosterol Peroxide Probes for Cellular Localization. Researchers at St. Jude and UCC have characterized medicinal mushroom Ganoderma lucidum compounds with anti-cancer activity, specifically signi?cant activity against breast cancer, thus having the potential to treat the most aggressive types of breast cancers such as triple negative breast cancer and in?ammatory breast cancer.
See the rest here:
Revive Therapeutics Signs Exclusive Worldwide License Agreement For Medicinal Mushroom Ganoderma Lucidum To Treat Cancer
PORTLAND, Ore., Aug. 17, 2021 (GLOBE NEWSWIRE) -- Chalice Brands Ltd. (CSE:CHAL) (OTCQB:CHALF) (“Chalice” or the “Company”), a premier consumer-driven cannabis company specializing in retail, production, processing, wholesale, and distribution, today announces it will report its second quarter 2021 results on Thursday, August 26, 2021 after market close.
Continue reading here:
Chalice Brands Ltd. Announces Timing of Its Second Quarter Earnings Results
MELBOURNE, Australia, Aug. 18, 2021 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, ‘Telix’, the ‘Company’) today announces that it has entered into a pan-cancer clinical collaboration with Merck KGaA, Darmstadt, Germany (‘Merck’), to conduct combination studies with one of Merck’s investigational proprietary DNA Damage Response Inhibitor (DDRi) molecules in combination with each of Telix’s TLX591 (177Lu-rosopatamab) and TLX250 (177Lu-girentuximab) molecularly targeted radiation (MTR) therapeutic programs. This clinical collaboration builds on the success of a strategic research collaboration agreement between Telix and Merck announced in August 2019.1
See the original post here:
Telix and Merck to Commence Pan-Cancer Clinical Combination Studies
MELBOURNE, Australia, Aug. 17, 2021 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, ‘Telix’, the ‘Company’) today announces that it has entered into a pan-cancer clinical collaboration with Merck KGaA, Darmstadt, Germany, to conduct combination studies with one of Merck KGaA, Darmstadt, Germany’s investigational proprietary DNA Damage Response Inhibitor (DDRi) molecules in combination with each of Telix’s TLX591 (177Lu-rosopatamab) and TLX250 (177Lu-girentuximab) molecularly targeted radiation (MTR) therapeutic programs. This clinical collaboration builds on the success of a strategic research collaboration agreement between Telix and Merck KGaA, Darmstadt, Germany announced in August 2019.1
Here is the original post:
Telix and Merck KGaA, Darmstadt, Germany, to Commence Pan-Cancer Clinical Combination Studies
– Bylvay is approved in the U.S. and EU as only once-daily drug indicated for patients with PFIC –
Follow this link:
Albireo and Genpharm Announce Agreement to Commercialize Bylvay™ (odevixibat) in Saudi Arabia and the Gulf Region
MELBOURNE, Australia, Aug. 18, 2021 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, ‘Telix’, the ‘Company’) today announces the initiation of two new investigator-led studies to evaluate the potential utility of the Company’s late-stage imaging portfolio in women’s health, initially in two sub-types of breast cancer with a significant unmet medical need. Both TLX591-CDx and TLX250-CDx have potential utility in breast cancer imaging, particularly for specific phenotypes that are not consistently well imaged using existing techniques.
Read the original here:
Two New Studies to Explore Telix Assets in Breast Cancer Theranostics